Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial-Reference-Cited by-同舟云学术

Ganaplacide (KAF156) plus lumefantrine solid dispersion formulation combination for uncomplicated Plasmodium falciparum malaria: an open-label, multicentre, parallel-group, randomised, controlled, phase 2 trial

Published:2023-09 Issue:9 Volume:23 Page:1051-1061
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Ogutu Bernhards,Yeka Adoke,Kusemererwa Sylvia,Thompson Ricardo,Tinto Halidou,Toure Andre Offianan,Uthaisin Chirapong,Verma Amar,Kibuuka Afizi,Lingani Moussa,Lourenço Carlos,Mombo-Ngoma Ghyslain,Nduba Videlis,N'Guessan Tiacoh Landry,Nassa Guétawendé Job Wilfried,Nyantaro Mary,Tina Lucas Otieno,Singh Piyoosh K,El Gaaloul Myriam,Marrast Anne Claire,Chikoto Havana,Csermak Katalin,Demin Ivan,Mehta Dheeraj,Pathan Rashidkhan,Risterucci Celine,Su Guoqin,Winnips Cornelis,Kaguthi Grace,Fofana Bakary,Grobusch Martin Peter

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference19 articles.

1. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019),2020

2. Evidence of artemisinin-resistant malaria in Africa;Balikagala;N Engl J Med,2021

3. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission;Kuhen;Antimicrob Agents Chemother,2014

4. Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway;LaMonte;Nat Commun,2020

5. Antimalarial activity of KAF156 in falciparum and vivax malaria;White;N Engl J Med,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ex vivo susceptibilities to ganaplacide and diversity in potential resistance mediators in Ugandan Plasmodium falciparum isolates;Antimicrobial Agents and Chemotherapy;2024-09-04

2. The emergence of artemisinin partial resistance in Africa: how do we respond?;The Lancet Infectious Diseases;2024-09

3. Discovery of pyridazinone derivatives bearing tetrahydroimidazo[1,2-a]pyrazine scaffold as potent inhibitors of transient receptor potential canonical 5 to ameliorate hypertension-induced renal injury in rats;European Journal of Medicinal Chemistry;2024-09

4. Hot melt extruded High-Dose amorphous solid dispersions containing lumefantrine and Soluplus;International Journal of Pharmaceutics;2024-09

5. In vitro evaluation of ganaplacide/lumefantrine combination against Plasmodium falciparum in a context of artemisinin resistance;Journal of Antimicrobial Chemotherapy;2024-08-29